Skip to content
Clinical Trials – home

Elvitegravir: An Antiretroviral Medication for HIV Treatment

1 / 1
trials open to patients / all trials
6+
Countries

In short

This article examines the use of elvitegravir, an integrase inhibitor, in clinical trials for HIV treatment. Elvitegravir is often studied as part of combination antiretroviral therapy regimens, particularly in the single-tablet formulation Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide). The trials investigate elvitegravir's efficacy, safety, and potential advantages compared to other HIV medications in various patient populations.

At a glance

Drug Formulations
Elvitegravir studied in combination therapies like Genvoya and Stribild
Patient Populations
Treatment-naive, treatment-experienced, HIV/HBV co-infected, HIV-2 infected
Primary Outcomes
Viral suppression, CD4 count changes, safety/tolerability
Comparator Treatments
Efavirenz-based regimens, raltegravir-based regimens
Duration of Studies
Typically 48-96 weeks
Special Considerations
Neuropsychiatric effects, bone/kidney health, drug interactions

What is elvitegravir?

Elvitegravir is an antiretroviral medication used to treat HIV-1 infection. It belongs to a class of drugs called integrase strand transfer inhibitors (INSTIs). Elvitegravir is often prescribed as part of combination antiretroviral therapy (ART) regimens to suppress HIV viral replication and improve immune function in people living with HIV.

How Elvitegravir Works

Elvitegravir works by inhibiting the HIV integrase enzyme, which is responsible for inserting the viral genetic material into the DNA of host cells. By blocking this crucial step in the HIV life cycle, elvitegravir prevents the virus from replicating and infecting new cells.

Uses of elvitegravir

Elvitegravir is primarily used for:

  • Treatment of HIV-1 infection in adults and adolescents
  • Part of initial antiretroviral therapy for treatment-naïve patients
  • Switching therapy for virologically suppressed patients

It is not approved for use in HIV-2 infection, although research is ongoing in this area.

Elvitegravir Formulations

Elvitegravir is available in several fixed-dose combination tablets:

  • Stribild: Contains elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate
  • Genvoya: Contains elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide

These single-tablet regimens simplify dosing and may improve adherence to treatment.

Effectiveness

Clinical trials have demonstrated the effectiveness of elvitegravir-containing regimens in achieving and maintaining viral suppression in HIV-1 infected patients. For example:

  • In a study comparing elvitegravir to raltegravir (another integrase inhibitor), both drugs showed similar efficacy in achieving viral suppression (HIV-1 RNA < 50 copies/mL) at 48 weeks.
  • A trial evaluating Genvoya (containing elvitegravir) showed that 91.7% of HIV/HBV co-infected patients maintained or achieved virologic suppression for both HIV and HBV at 48 weeks of therapy.

Side Effects

Common side effects of elvitegravir-containing regimens may include:

  • Nausea
  • Diarrhea
  • Headache
  • Fatigue

Some patients may experience neurological or psychiatric side effects. A study found that the frequency of these complaints in patients taking elvitegravir reaches on average 20-30% during clinical trials. These may include:

  • Sleep disturbances
  • Anxiety
  • Depression
  • Dizziness

Drug Interactions

Elvitegravir is often co-formulated with cobicistat, a pharmacokinetic enhancer. This combination can lead to significant drug interactions. Patients should inform their healthcare providers about all medications they are taking, including over-the-counter drugs and supplements.

Use in Special Populations

Elvitegravir-containing regimens have shown promise in certain special populations:

  • HIV/HBV co-infection: Genvoya (containing elvitegravir) has demonstrated efficacy in patients co-infected with HIV and hepatitis B virus.
  • Renal impairment: Some elvitegravir-containing regimens (e.g., Genvoya) may be suitable for patients with mild to moderate renal impairment.

Ongoing Research

Research on elvitegravir is ongoing, including:

  • Evaluation of its use in HIV-2 infection
  • Comparison with other antiretroviral regimens for post-exposure prophylaxis (PEP)
  • Assessment of its long-term safety and efficacy

In conclusion, elvitegravir is an important component of modern HIV treatment regimens. Its effectiveness, convenient dosing in single-tablet formulations, and generally favorable side effect profile make it a valuable option for many patients living with HIV. However, as with all medications, its use should be carefully considered and monitored by healthcare professionals.

Questions people often ask

Conditions where Elvitegravir is being studied

Each condition opens its own overview and trial list

Trials with Elvitegravir

Recruiting trials first

See all 1 →
Quick filters
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.